Pulse Biosciences Inc. (PLSE) had quite the Friday, with shares climbing sharply after the medical device company released clinical trial data that suggests its heart treatment technology might actually deliver on its promise.
The stock was trading up 38% at $14.95, accompanied by trading volume that tells its own story. About 1.68 million shares changed hands during the session, compared to a typical daily volume of around 183,000 shares. That's the kind of enthusiasm you see when investors think they're onto something real.
The Science Behind the Surge
On February 6, Pulse Biosciences unveiled results from its nPulse Cardiac Catheter first-in-human feasibility study, presenting the data at the Annual AF Symposium 2026 in Boston. The study evaluated 165 patients total, successfully treating 150 of them for atrial fibrillation.
What caught attention wasn't just that the treatment worked, but how it worked. The device demonstrated rapid procedure times combined with minimal adverse effects, which in medical device development is essentially hitting the sweet spot. You want something that's both effective and safe, obviously, but speed matters too when you're dealing with cardiac procedures.
"These results validate the safety, effectiveness, lesion quality, and speed benefits that clearly differentiate the nPulse Cardiac Catheter Ablation System as a first-in-class system," said Paul LaViolette, CEO and Co-Chairman of Pulse Biosciences.
Why This Matters for Heart Patients
Here's the practical application: atrial fibrillation treatments currently face recurrence rates between 20% and 25%. That's the percentage of patients whose irregular heartbeat returns after treatment. If Pulse Biosciences' technology can meaningfully reduce those recurrence rates, that's a genuine advancement in cardiac care.
The company's approach uses proprietary nPulse technology, which delivers nanosecond pulses of electrical energy to clear cells non-thermally. Translation: it doesn't rely on heat to destroy tissue, which is the traditional ablation approach. That difference in mechanism could explain the favorable safety profile.
Looking ahead, Pulse Biosciences is gearing up to expand the trial, treating additional patients in both Europe and the United States as it launches a pivotal IDE study. That's the regulatory pathway toward potential approval.
What the Charts Say
From a technical perspective, Pulse Biosciences is showing interesting positioning. The stock is trading 38.5% above its 20-day simple moving average and 39.8% above its 50-day SMA. That's a bullish setup by most measures, suggesting momentum could carry higher.
The RSI sits at 46.10, right in neutral territory. That means the stock isn't overbought yet, which leaves room for continued upside if the enthusiasm persists. However, the MACD indicator is below its signal line, which typically signals bearish pressure and suggests traders should stay alert.
Key levels to watch: support sits at $16.50, with resistance at $20.00. A breakthrough above $20 would signal continuation of the upward trend, while falling below $16.50 might indicate the rally is losing steam.
Zooming out to the bigger picture, the stock is down 9.57% over the past twelve months, which shows this hasn't been a smooth ride. Currently trading at 57.4% of its 52-week range, the shares are closer to the high end than the low, but still have ground to recover.
The combination of technical indicators presents a mixed picture that warrants careful monitoring. The moving averages look bullish, momentum is neutral, and the MACD suggests caution. In other words, traders should watch those support and resistance levels closely in the coming sessions.
